FDA Approval and Age Restrictions for Gvoke
Gvoke (glucagon injection) is FDA-approved for emergency treatment of severe hypoglycemia in patients with diabetes aged 2 years and older.[1] It is not approved for children under 2 years, including toddlers (typically 1-3 years old). The prescribing information explicitly states safety and effectiveness have not been established in pediatric patients below age 2.[1][2]
Safety Data in Young Children
Clinical trials supporting Gvoke's approval included children as young as 2 but excluded infants and younger toddlers due to limited data.[1] No specific safety studies exist for toddlers under 2, so risks like vomiting, injection site reactions, or rare hypersensitivity cannot be reliably assessed in that group. Off-label use in children under 2 lacks robust evidence and is not recommended by manufacturers or guidelines.[2]
What Happens in Toddlers Under 2?
For severe hypoglycemia emergencies in very young children, alternatives like glucagon emergency kits (e.g., Glucagon Emergency Kit, approved for all ages including neonates) are preferred, as they have broader pediatric data.[3] Guidelines from the American Diabetes Association recommend age-appropriate glucagon formulations but caution against unapproved uses.[4] Consult a pediatric endocrinologist immediately for toddlers—do not administer Gvoke without medical guidance.
Risks and Side Effects in Kids
Common side effects in approved ages (2+) include nausea (27%), vomiting (11%), and headache (10%), with higher rates in younger patients.[1] In unstudied toddlers, unknown factors like immature metabolism could amplify risks. Overdose risks include hypertension or hypoglycemia rebound.[2]
Alternatives for Toddlers with Type 1 Diabetes